200 Miles - One Patient's Journey for MMRF

Patients with heavily pretreated myeloma tended to have “really amazing results” with the CAR-T cell therapy, Carvykti.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

The Food and Drug Administration approved the CAR-T cell therapy, Carvykti, for previously treated patients with multiple myeloma.

In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.

There is no difference in treatment for non-secretory multiple myeloma and multiple myeloma, an expert told CURE®.

Of everything I've ever done, I wonder how my multiple myeloma came to be.